Summary
Dehydrated Alcohol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Coeliac Disease (Refractory / RCD) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Coeliac Disease (Refractory / RCD). ClinicalTrials.gov lists 8 registered trials linking Dehydrated Alcohol to Coeliac Disease (Refractory / RCD): 2 are currently recruiting; 5 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT06316908). The largest enrolment is 180 participants (NCT04951804). Registration activity spans 2006 to 2023. No published literature item is linked to Dehydrated Alcohol and Coeliac Disease (Refractory / RCD) in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Celiac Disease ranks 73 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: No spontaneous remission — autoimmune injury continues as long as gluten is consumed; villous atrophy persists in 30-40% at 5 years even on gluten-free diet (GFD) due to cross-contamination.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 43.5 (trials 23.5, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 2 recruiting, 0 active / not yet recruiting, 5 completed, 1 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | ANKS1B |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT06316908 | Permanent Celiac Plexus Block: Comparison of Pain Score in Unilateral and Bilateral Posterior Percutaneous Approach 2020 | completed | Phase 4 | 30 |
| NCT00974948 | Trial of Endoscopic Ultrasound (EUS) - Guided Celiac Plexus Neurolysis 2006 | completed | Phase 3 | 100 |
| NCT03152487 | Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis 2017 | completed | Not applicable | 28 |
| NCT01913574 | Efficacy Study of Acupuncture to Treat the Upper Abdominal Pain of Cancer Patients 2013 | completed | Not applicable | 14 |
| NCT03770247 | Intraoperative Versus CT Guided Celiac Plexus Neurolysis in Unresectable Pancreatic Cancer 2018 | completed | Not applicable | 76 |
| NCT06160323 | Upfront EUS CGN/CPN vs Conventional Step up Approach for Inoperable Painful Pancreatic Cancer 2023 | recruiting | Not applicable | 94 |
| NCT04951804 | EUS-CPN With and Without Bupivacaine 2021 | recruiting | Not applicable | 180 |
| NCT03886298 | Radiofrequency Splanchnic Denervation Versus Retrocrural Neurolytic Celiac Block for Pancreatic Cancer Pain 2019 | status unknown | Not applicable | 60 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ANKS1B. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Dehydrated Alcohol approved for Coeliac Disease (Refractory / RCD)?
Dehydrated Alcohol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Coeliac Disease (Refractory / RCD) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Coeliac Disease (Refractory / RCD). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Dehydrated Alcohol in clinical trials for Coeliac Disease (Refractory / RCD)?
ClinicalTrials.gov lists 8 registered trials linking Dehydrated Alcohol to Coeliac Disease (Refractory / RCD): 2 are currently recruiting; 5 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT06316908). The largest enrolment is 180 participants (NCT04951804). Registration activity spans 2006 to 2023.
What does the evidence show for Dehydrated Alcohol in Coeliac Disease (Refractory / RCD)?
Dehydrated Alcohol has 5 completed registered trials for Coeliac Disease (Refractory / RCD) but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ANKS1B. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.